Ireland
--:--IST
Latest
Clinical Trials in Sweden / NCT06658704
Active, not recruiting Not applicable

Understanding Motivation Towards Exercise to Enhance Physical Activity on Prescription Adherence

NCT06658704 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2024-11-06
Last updated
2026-05-01

Condition(s) studied

Physical Inactivity

Investigational drug(s) / intervention(s)

Supervised exercise in a group settingUsual care (Physical activity on Prescription)

Supervised exercise in a group setting: Participants are invited to a 16 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first two weeks and then two sessions per week for week 3-16.

Usual care (Physical activity on Prescription): Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks.

Study summary

The goal of this clinical trial is to explore effectiveness on physical activity, function and psychometrics in relation to an exercise intervention in physically inactive middle-aged men and women. The main questions it aims to answer are:

* Is the exercise intervention effective in increasing physical activity, function and motivation towards exercise? Is there an intervention effect in physical activity, function and psychometrics at 6-, 12- and 24 months post baseline?
* Can barriers and facilitators towards increased physical activity be identified in the two groups of the study?

All participants will first receive standard care for physically inactive patients, i.e. Physical activity on Prescription (PaP), followed by allocation to an exercise intervention (EI) group or a control group. The EI group will be offered an additional exercise intervention for 16 weeks consisting of 1-2 training sessions per week of a combination of aerobic and resistance training at a private fitness centre. The control group will be asked to adhere to their PaP.

Researchers will assess physical activity, function and psychometrics in the two groups at 6-, 12- and 24 months to evaluate the intervention effect. Additionally, interviews with the participants in the control and EI groups will be performed in order to explore barriers and facilitators towards increased physical activity in formerly inactive patients.

Eligibility

Sex
ALL
Min age
40 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Physically inactive persons as defined as not meeting the current recommendations of at least 150 minutes of moderate to vigorous physical activity per week. This criterion is self-assessed by potential participants. * Age 40-60 years Exclusion Criteria: * Physical disability that affects the ability to perform the exercise intervention. * Heart failure or severe degenerative disease, e.g. malignant cancer, multiple sclerosis etc. * Myocardial infarction or stroke during the last 12 months. * Heart conditions including angina pectoris that is worsened with exercise. * Neuromuscular, musculoskeletal, or rheumatic conditions that is worsened with exercise. * Hypertension grade III, i.e. systolic blood pressure above 180 mmHg and/or diastolic blood pressure over 110 mmHg.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Umeå University Umeå Västerbotten County

More Umeå University trials in Sweden

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06658704 on ClinicalTrials.gov ↗ ← All trials in Sweden